FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048387531> ?p ?o ?g. }

• W3048387531 endingPage "1525" @default.
• W3048387531 startingPage "1518" @default.
• W3048387531 abstract "•This trial prospectively evaluated the predictive capacity of the HRD biomarker for pathologic response in early TNBC.•Pathologic responses to preoperative cisplatin or taxane monotherapy in germline BRCA1/2 wild-type TNBC were similar.•HRD score was not predictive of pathologic response to either cisplatin or paclitaxel chemotherapy.•HRD testing cannot be recommended as a tool to select chemotherapy agents in the management of early-stage TNBC. BackgroundCisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel.Patients and methodsThis prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I–III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response.ResultsOne hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39–23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19–4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy.ConclusionsIn this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy. Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I–III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response. One hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39–23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19–4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy. In this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy." @default.
• W3048387531 created "2020-08-18" @default.
• W3048387531 creator A5015821699 @default.
• W3048387531 creator A5019041034 @default.
• W3048387531 creator A5021488024 @default.
• W3048387531 creator A5022192136 @default.
• W3048387531 creator A5024804370 @default.
• W3048387531 creator A5026024346 @default.
• W3048387531 creator A5032785430 @default.
• W3048387531 creator A5041593789 @default.
• W3048387531 creator A5051532432 @default.
• W3048387531 creator A5052268581 @default.
• W3048387531 creator A5056530735 @default.
• W3048387531 creator A5066125634 @default.
• W3048387531 creator A5068666503 @default.
• W3048387531 creator A5070245248 @default.
• W3048387531 creator A5071874576 @default.
• W3048387531 creator A5072850149 @default.
• W3048387531 creator A5073728088 @default.
• W3048387531 creator A5075153453 @default.
• W3048387531 creator A5075889627 @default.
• W3048387531 creator A5079016578 @default.
• W3048387531 creator A5085329460 @default.
• W3048387531 date "2020-11-01" @default.
• W3048387531 modified "2023-10-17" @default.
• W3048387531 title "TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker" @default.
• W3048387531 cites W1965225327 @default.
• W3048387531 cites W1998475737 @default.
• W3048387531 cites W2074952360 @default.
• W3048387531 cites W2086064725 @default.
• W3048387531 cites W2094523134 @default.
• W3048387531 cites W2096145980 @default.
• W3048387531 cites W2096745115 @default.
• W3048387531 cites W2100419317 @default.
• W3048387531 cites W2105496345 @default.
• W3048387531 cites W2109772731 @default.
• W3048387531 cites W2118605519 @default.
• W3048387531 cites W2142460765 @default.
• W3048387531 cites W2142486051 @default.
• W3048387531 cites W2147629880 @default.
• W3048387531 cites W2158742893 @default.
• W3048387531 cites W2168409298 @default.
• W3048387531 cites W2295085830 @default.
• W3048387531 cites W2430731787 @default.
• W3048387531 cites W2528228811 @default.
• W3048387531 cites W2779333875 @default.
• W3048387531 cites W2801956643 @default.
• W3048387531 cites W2807037141 @default.
• W3048387531 cites W2895846919 @default.
• W3048387531 cites W2946912773 @default.
• W3048387531 cites W2946918907 @default.
• W3048387531 cites W2947926709 @default.
• W3048387531 cites W3008697231 @default.
• W3048387531 cites W4211006558 @default.
• W3048387531 doi "https://doi.org/10.1016/j.annonc.2020.08.2064" @default.
• W3048387531 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8437015" @default.
• W3048387531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32798689" @default.
• W3048387531 hasPublicationYear "2020" @default.
• W3048387531 type Work @default.
• W3048387531 sameAs 3048387531 @default.
• W3048387531 citedByCount "43" @default.
• W3048387531 countsByYear W30483875312021 @default.
• W3048387531 countsByYear W30483875312022 @default.
• W3048387531 countsByYear W30483875312023 @default.
• W3048387531 crossrefType "journal-article" @default.
• W3048387531 hasAuthorship W3048387531A5015821699 @default.
• W3048387531 hasAuthorship W3048387531A5019041034 @default.
• W3048387531 hasAuthorship W3048387531A5021488024 @default.
• W3048387531 hasAuthorship W3048387531A5022192136 @default.
• W3048387531 hasAuthorship W3048387531A5024804370 @default.
• W3048387531 hasAuthorship W3048387531A5026024346 @default.
• W3048387531 hasAuthorship W3048387531A5032785430 @default.
• W3048387531 hasAuthorship W3048387531A5041593789 @default.
• W3048387531 hasAuthorship W3048387531A5051532432 @default.
• W3048387531 hasAuthorship W3048387531A5052268581 @default.
• W3048387531 hasAuthorship W3048387531A5056530735 @default.
• W3048387531 hasAuthorship W3048387531A5066125634 @default.
• W3048387531 hasAuthorship W3048387531A5068666503 @default.
• W3048387531 hasAuthorship W3048387531A5070245248 @default.
• W3048387531 hasAuthorship W3048387531A5071874576 @default.
• W3048387531 hasAuthorship W3048387531A5072850149 @default.
• W3048387531 hasAuthorship W3048387531A5073728088 @default.
• W3048387531 hasAuthorship W3048387531A5075153453 @default.
• W3048387531 hasAuthorship W3048387531A5075889627 @default.
• W3048387531 hasAuthorship W3048387531A5079016578 @default.
• W3048387531 hasAuthorship W3048387531A5085329460 @default.
• W3048387531 hasBestOaLocation W30483875311 @default.
• W3048387531 hasConcept C121608353 @default.
• W3048387531 hasConcept C126322002 @default.
• W3048387531 hasConcept C143998085 @default.
• W3048387531 hasConcept C185592680 @default.
• W3048387531 hasConcept C2775930923 @default.
• W3048387531 hasConcept C2776694085 @default.
• W3048387531 hasConcept C2777292972 @default.
• W3048387531 hasConcept C2777511904 @default.
• W3048387531 hasConcept C2778239845 @default.
• W3048387531 hasConcept C2778336483 @default.
• W3048387531 hasConcept C2780110267 @default.

• next